Edgewise Therapeutics

News

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.